Enhanced effects of bleomycin on pulmonary function disturbances in patients with decreased renal function due to cisplatin

被引:22
作者
Sleijfer, S
vanderMark, TW
Koops, HS
Mulder, NH
机构
[1] UNIV GRONINGEN HOSP,DEPT INTERNAL MED,DIV MED ONCOL,9700 RB GRONINGEN,NETHERLANDS
[2] UNIV GRONINGEN HOSP,DEPT INTERNAL MED,DIV LUNG FUNCT,9700 RB GRONINGEN,NETHERLANDS
[3] UNIV GRONINGEN HOSP,DEPT SURG ONCOL,9700 RB GRONINGEN,NETHERLANDS
关键词
bleomycin; cisplatin; testicular cancer; lung function; renal function;
D O I
10.1016/0959-8049(95)00644-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We examined whether cisplatin-induced nephrotoxicity augmented bleomycin-induced pulmonary toxicity in patients with testicular cancer treated with etoposide and cisplatin with (BEP) or without bleomycin (EP). Before and at 3-week intervals during chemotherapy, creatinine clearance and lung functions were measured. In patients receiving BEP, deterioration of renal function correlated with a decrease in transfer factor of the lungs for carbon monoxide (T-LCO) and vital capacity (VC), parameters known to reflect bleomycin-induced pulmonary effects. Other lung functions did not correlate with renal function. In the EP group, no relationships were observed at all. These observations suggest enhanced pulmonary effects of bleomycin when combined with cisplatin. Therefore, attention should be paid to the potential development of bleomycin-induced pulmonary toxicity in patients treated with BEP.
引用
收藏
页码:550 / 552
页数:3
相关论文
共 16 条
  • [1] BENNETT WM, 1980, CANCER TREAT REP, V64, P921
  • [2] PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE
    COCKCROFT, DW
    GAULT, MH
    [J]. NEPHRON, 1976, 16 (01) : 31 - 41
  • [3] Comis R L, 1992, Semin Oncol, V19, P64
  • [4] CROOKE ST, 1987, CANC TREAT REP, V61, P1631
  • [5] BLEOMYCIN PULMONARY TOXICITY - ITS RELATIONSHIP TO RENAL DYSFUNCTION
    DALGLEISH, AG
    WOODS, RL
    LEVI, JA
    [J]. MEDICAL AND PEDIATRIC ONCOLOGY, 1984, 12 (05): : 313 - 317
  • [6] DENTINO M, 1978, CANCER, V41, P1274, DOI 10.1002/1097-0142(197804)41:4<1274::AID-CNCR2820410410>3.0.CO
  • [7] 2-F
  • [8] MCLEOD BF, 1987, CANCER, V60, P2617, DOI 10.1002/1097-0142(19871201)60:11<2617::AID-CNCR2820601107>3.0.CO
  • [9] 2-D
  • [10] OKEW MM, 1981, CANC TREAT REP, V65, P485